Scottish Medicines Consortium decision on Afinitor® (Everolimus)

The Scottish Medicines Consortium (SMC) has issued a positive recommendation for everolimus, which has been accepted for use in NHS Scotland, as a treatment option for advanced kidney cancer patients who have failed on or after one previous vascular endothelial growth factor (VEGF)-targeted therapy.
Source: Pharmacy Europe - Category: Drugs & Pharmacology Authors: Tags: *** Editor's Pick Practical therapeutics Industry News Oncology advanced kidney cancer everolimus Latest News scottish medicines consortium VEGF-targeted therapy Source Type: news